Sovargen Co., Ltd. has dosed the first patient in a Phase 1b/2a clinical trial evaluating paxalisib for the treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE